Biogen Idec announced today that the FDA has accepted the company's new hemophilia B drug application and will begin its regulatory review. The review is expected to take 10 months, according to the AP.
Hemophilia B is a rare, inherited disorder in which the ability of a person's blood to clot is impaired.
Biogen's recombinant factor IX Fc fusion protein (rFIXFc) is a clotting factor that uses the company's FDA-approved proprietary monomeric Fc fusion technology to provide longer-lasting protection from bleeding.
"We are encouraged by the FDA's acceptance of our application, as we believe rFIXFc has the potential to transform the care of hemophilia B by allowing for less frequent injections and helping patients to maintain low annualized bleeding rates," Dr. Glenn Pierce, a senior vice president of Biogen Idec, is quoted as saying in the company press release. "We are working with the FDA to bring the first major treatment advance for the hemophilia B community in 15 years."
Not only does the drug potentially provide better protection from bleeding, but it can also significantly reduce the 100+ injections a year some hemophilia B patients now receive to aid clotting, according to Biogen Idec. The compay says B-LONG, the largest registrational phase 3 clinical study ever conducted for hemophilia B, supported these findings.
The article FDA Begins Review of Biogen's Hemophilia B Drug originally appeared on Fool.com.
Fool contributor Justin Loiseau has no position in any stocks mentioned. You can follow him on Twitter, @TMFJLo, and on Motley Fool CAPS, @TMFJLo.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.